Antibody Drug Conjugates Market is expected to exhibit a strong 19% CAGR over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR). Global Antibody Drug Conjugates Market Driven by Growing Demand for Effective Cancer Medication. Antibody Drug Conjugates Market is segmented based on type, product, technology, application, end user, and region.
Competitive Analysis:
Leading players in the global antibody drug conjugates market include Oxford BioTherapeutics, Heidelberg Pharma, Synthon, Mersana Therapeutics, Progenics Pharmaceuticals, Astellas Pharma/Agensys, Bayer Healthcare, AbbVie Inc., Millennium Pharmaceuticals, Celldex Therapeutics, Pfizer Inc., Immunomedics, Antikor, Agensys Inc., Concortis Biotherapeutics, Genentech, Roche Holding AG, ImmunoGen Inc., and Seattle Genetics.
Get Free Sample “Antibody Drug Conjugate Market Research Report – Forecast to 2023” at: https://www.marketresearchfuture.com/sample_request/1113
The report provides readers with a comprehensive view of the global antibody drug conjugates market, enabling a complete understanding of the market’s major drivers and restraints for the readers. The major trends operating on the antibody drug conjugates market are also studied in detail in the report, providing readers with a clear picture of the dynamics within the market. Leading players in the global antibody drug conjugates market are also profiled in the report to provide readers with a clear view of the competitive dynamics of the market. Increasing Demand in Cancer Treatment to Drive Antibody Drug Conjugates Market
Antibody drug conjugates are a formulation in which specific antibodies can survive for long periods of time and deliver long-lasting, effective remedies against several diseases. The three parts of antibody drug conjugates are the antibody for binding, cytotoxic medical compounds for destroying the targeted cells, and a linker to join these two parts together and remain in a stable configuration. These formulations have become widely popular in the global healthcare sector as they represent a viable method of treating several diseases, including various types of cancers. The use of a specific antibody for binding to specific sites allows for highly targeted action of the medicine, while studies have shown that the cytotoxic agent is more than 100X as powerful when used in an antibody drug conjugate as when used in isolation.
The increasing demand for effective medications against cancer is likely to be the major driver for the global antibody drug conjugate market over the forecast period. Cancer research has emerged as a major driver for the healthcare sector, as the growing threat of cancer and the growing economic burden of the disease around the world has driven large-scale investment in the development of effective cancer medication. This is likely to drive further product development in the antibody drug conjugates market over the coming years, as leading players attempt to develop effective remedies for various types of cancer.
In July 2019, an early phase trial of patients with heavily pretreated HER2-related cancers showed promising activity from the antibody drug conjugate trastuzumab duocarmazine. The increasing range of the application of antibody drug conjugates is likely to be a key driver for the antibody drug conjugates market over the forecast period.
Segmentation:
The global antibody drug conjugate market is segmented based on type, product, technology, application, end user, and region.
Based on type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
Based on application, the global antibody drug conjugate market is segmented into leukemia, prostate cancer, kidney cancer, pancreatic cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further divided into acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
Based on product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
Based on technology, the global antibody drug conjugate market is classified into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
Based on end user, the global antibody drug conjugate market is classified into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
Regional Analysis:
The Americas hold the dominant share in the global antibody drug conjugates market due to the growing medical research industry in the region and the growing demand for effective cancer medication in the region. Europe is the second largest market, followed by Asia Pacific. The latter is expected to exhibit the fastest growth over the forecast period due to the growing healthcare sector and the increasing threat of cancer in this region.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Antibody Drug Conjugate Market, By Type
6.1 Introduction
6.2 Monoclonal Antibodies
6.2.1 Market Estimates & Forecast, 2017–2023
6.3 Linker
6.3.1 Market Estimates & Forecast, 2017–2023
6.4 Drug/Toxin
6.4.1 Market Estimates & Forecast, 2017–2023
6.5 Others
Chapter 7. Global Antibody Drug Conjugate Market, By Application
7.1 Introduction
7.2 Leukemia
7.2.1 Market Estimates & Forecast, 2017–2023
7.2.2 Acute Myeloid Leukemia (AML)
7.2.2.1 Market Estimates & Forecast, 2017–2023
7.2.3 Chronic Myeloid Leukemia (CML)
7.2.3.1 Market Estimates & Forecast, 2017–2023
7.2.4 Acute Lymphocytic Leukemia (ALL)
7.2.4.1 Market Estimates & Forecast, 2017–2023
7.2.5 Chronic Lymphocytic Leukemia (CLL)
7.2.5.1 Market Estimates & Forecast, 2017–2023
Continued…
LIST OF TABLES:
Table 1 Antibody Drug Conjugate Industry Synopsis, 2017–2023
Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Antibody Drug Conjugate Market, By Region, 2017–2023, (USD Million)
Table 4 Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)
Table 5 Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)
Table 6 Antibody Drug Conjugate Market, By Product, 2017–2023, (USD Million)
Table 7 Antibody Drug Conjugate Market, By Technology, 2017–2023, (USD Million)
Table 8 Antibody Drug Conjugate Market, By End-User, 2017–2023, (USD Million)
Continued…
LIST OF FIGURES:
Figure 1 Research Process
Figure 2 Segmentation For Antibody Drug Conjugate Market
Figure 3 Segmentation Market Dynamics For Antibody Drug Conjugate Market
Figure 4 Global Antibody Drug Conjugate Market Share, By Type, 2016
Figure 5 Global Antibody Drug Conjugate Market Share, By Application, 2016
Figure 6 Global Antibody Drug Conjugate Market Share, By Product, 2016
Figure 8 Global Antibody Drug Conjugate Market Share, By Technology, 2016
Figure 9 Global Antibody Drug Conjugate Market Share, By End-User, 2016
Figure 10 Global Antibody Drug Conjugate Market Share, By Region, 2016
Continued…
Browse more details at: https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Amanora Chambers,
Magarpatta Road, Hadapsar
Pune – 411028
Maharashtra, India+1 646 845 9312
